Volume 90 Issue 32 | p. 21 | Concentrates
Issue Date: August 6, 2012

Cleveland BioLabs Inks Pact With Russia

Department: Business
Keywords: Russia, stem cells, pharmaceuticals

Cleveland BioLabs has signed a $4 million agreement with the Russian Ministry of Industry & Trade for CBLB612, a drug in development for stimulation of hematopoietic stem cell proliferation and mobilization. The contract, issued under Russia’s Pharma 2020 initiative, provides funding over a three-year period to support research through Phase II clinical trials. Cleveland BioLabs says CBLB612 is a candidate for use in bone marrow transplants.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment